Kite Lake Sends Letter to Inmarsat Plc Board of Directors Following Letters From Oaktree and Rubric
5.11.2019 18:46:00 EET | Business Wire | Press release
Kite Lake Capital Management (UK) LLP which, as Investment Manager / Sub-Advisor for and on behalf of underlying funds, has an economic interest in 17,770,258 shares (over 3.8% of the outstanding equity) of Inmarsat Plc ("Inmarsat") has today announced that it has sent a letter to the Board of Directors of Inmarsat following earlier letters from Oaktree Capital Management, L.P. and Rubric Capital Management LP.
The full text of the letter is set out below.
The Board of Directors of Inmarsat Plc
99 City Road
London, EC1Y 1AX
UK
5 November 2019
To the Board of Directors of Inmarsat Plc:
Kite Lake Capital Management (UK) LLP (“Kite Lake”), as Investment Manager / Sub-Advisor for and on behalf of underlying funds, has an economic interest in 17,770,258 shares of Inmarsat Plc (over 3.8% of the outstanding equity).
Kite Lake notes the letter published by Oaktree Capital Management (“Oaktree”) on 5 November 2019, and we are in full agreement with the points Oaktree raises. This is an almost unprecedented situation, in which a spectrum asset (“Ligado”), appears to have been ascribed limited to zero value in the analysis of the fairness of the Consortium Scheme price. This is evidenced by the lack of any reference in the Scheme document to Ligado’s potential value, and on the 1Q 2019 Inmarsat Earnings Call held 1st May 2019: To quote CEO Rupert Pearce “… there will be no Ligado revenues in 2019 and we’re not planning for them to return to paying us, anytime in the near future.”
It has since been widely reported that Ligado could very well receive final regulatory approval imminently after over 10 years of delays. This approval is potentially only weeks away, and at the very minimum, we believe that the Board should delay the Scheme hearing until just prior to the Long Stop Date of 10 December 2019 to allow as much time as possible to clarify the regulatory position of Ligado to determine the best course of action with respect to Inmarsat’s current shareholders.
The question we pose to the Board is simple: given the material prospect of regulatory approval prior to the Long Stop Date, would the Board recommend a $7.09 offer if it was made today? We believe the answer should be a categorical no.
We also note the letter of today's date from Rubric Capital Management LP ("Rubric"). Like Rubric, in May 2019, Kite Lake voted for the Scheme, having moved shares owned into “cash” from “swap”, at the expense of the funds managed by Kite Lake at the request of Consortium advisors (on the basis that the vote was expected to be very close). We did so after several discussions with one of the Financial Advisors of the Consortium, with the understanding that if there was a material development with respect to Ligado prior to the Scheme Sanction, the Board would have the ability to either change its recommendation of the Scheme or delay the Scheme hearing.
We believe the Board must do the right thing for existing shareholders and delay the Scheme hearing as long as possible in order to clarify the current state of Ligado. We don’t see any disadvantage to existing shareholders in doing so. The shareholders deserve nothing less.
We note the announcement made by Inmarsat today. If the Board declines to engage with the Oaktree request, Kite Lake’s current intention is to attend the Scheme Hearing, and to indicate our concerns relating to the proposed transaction to the Court.
Sincerely,
Jamie Sherman
Partner
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191105005824/en/
Contact information
Jamie Sherman
+44 207 052 8310
jamie.sherman@kitelake.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
